Key Decisions for Selecting Bispecific Antibodies in Follicular Lymphoma

In this episode, Dr Christopher Flowers and Dr John Allan discuss their experience with the use of CD20xCD3 bispecific antibodies in the treatment of patients with relapsed/refractory follicular lymphoma. They also their thoughts on key ongoing clinical trials with bispecific antibodies that they are excited about for their potential to change the standard of care for patients with follicular lymphoma. The overall discussion between these 2 experts includes:

• Using bispecific antibodies in clinical practice for relapsed/refractory follicular lymphoma, including an overview of the drugs mosunetuzumab, epcoritamab, and odronextamab
• Monitoring and managing CRS and ICANS when prescribing bispecific antibodies to patients with relapsed/refractory follicular lymphoma 
• Promising ongoing clinical trials with bispecific antibodies for patients with follicular lymphoma, such as EPCORE FL-1 with epcoritamab, OLYMPIA-5 with odronextamab, and SOUNDTRACK-F1 with surovatamig

Presenters: 

Dr Christopher Flowers Division Head, Division of Cancer MedicineChair, Professor, Department of Lymphoma/MyelomaJohn Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer MedicineMD Anderson Cancer CenterHouston, Texas

Dr John AllanAssociate Professor of Clinical MedicineDivision of Hematology and Medical OncologyWeill Cornell MedicineNew York, New York

Content based on an online CME program supported by Regeneron Pharmaceuticals, Inc.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.